EU approves Novo’s once-weekly diabetes therapy
European regulators have issued a green light for Novo Nordisk’s once-weekly diabetes therapy Ozempic.
Read More
Tag: GLP-1
Researchers repurpose diabetes drug for brain pressure
Research led by the University of Birmingham indicates that a GLP-1 agonist drug, currently used to lower blood sugar in people with type II diabetes, could be repurposed to treat raised brain pressure.
Read More
EU approves CV benefit claim for Novo’s Victoza
Novo Nordisk’s diabetes drug Victoza is now approved in Europe as the only GLP-1 analogue with a label including prevention of cardiovascular events.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
